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Heart Failure (HF) is a common syndrome caused by different pathologies of the 
cardiovascular system that result in impairment of the ventricles to fill or eject blood. 
Heart failure is one of the most common causes of hospitalization in United States with 
a very high cost to the healthcare system. There are 880,000 new heart failure 
diagnoses per year in the United States and 5 million cases currently identified in the 
US.  (1-2). In this chapter we will focus on the etiologies of the left ventricle (LV) 
dysfunction, presentation and, the acute and chronic management of heart failure.  
Etiologies of Heart failure 
There is a broad spectrum of pathologies that cause LV dysfunction.  The etiologies of 
systolic and diastolic dysfunction include of coronary artery disease, hypertension, 
valvular heart disease, to more rare etiologies such as infiltrative disorders and parasitic 
infections. Table 1. lists the most common of the etiologies of HF encountered by 
clinicians  
Table 1 
Etiologies of Heart failure 
Myocardial disease 
1. Coronary artery disease 
2. Hypertension 
3. Cardiomyopathy 
                a. Familial 
                      i. Hypertrophic 
                      ii. Dilated 
                      iii. Arrhythmogenic right ventricular cardiomyopathy 
                      iv. Restrictive 
                      v.  Left ventricular non-compaction 
            b. Acquired 
                    i.   Myocarditis  
 
                               Infective 
• Bacterial 
• Spirochaetal 
• Fungal 
• Protozoal 
• Parasitic 
• Rickettsial 
• Viral 
 
Immune-mediated 
• Tetanus toxoid, vaccines, serum sickness 
• Drugs 
• Lymphocytic/giant cell myocarditis 
• Sarcoidosis 
• Autoimmune 
• Eosinophilic (Churg-Strauss) 
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                                Toxic 
• Drugs (Chemotherapy, cocaine) 
• Alcohol 
• Heavy metals (copper, iron, lead) 
 
                       ii.   Endocrine/nutritional 
• Phaeochromocytoma  
• Vitamin deficiency (e.g. thiamine) 
• Selenium deficiency 
• Hypophosphataemia 
• Hypocalcaemia 
 
                      iii.   Pregnancy 
 
                    iv. Infiltration 
• Amyloid 
• Malignancy 
 
Valvular Heart Disease 
• Mitral 
• Aortic 
• Tricuspid 
• Pulmonary 
 
Pericardial Disease 
• Constrictive pericarditis 
• Pericardial effusion 
Congenital Heart Disease 
Arrhythmia 
• Tachycardia (atrial, Ventricular) 
• Bradyarrhythmia (Sinus node dysfunction, Atrioventricular block) 
High Output States 
• Anemia 
• Sepsis 
• Thyrotoxicosis 
• Paget’s disease 
• Arteriovenous fistula 
Volume Overload 
• Renal failure 
• Iatrogenic (post-operative fluid infusion) 
 
Table 1. Etiologies of Heart Failure. Adapted from European Society of Cardiology Guidelines, European Heart 
Journal, 2012 
 
Acute Heart Failure  
Common presenting symptoms of HF can include mild shortness of breath, peripheral 
edema and fatigue, to more severe symptoms such as hypotension, syncope, shock 
and respiratory failure. A thorough history and physical exam is critical in diagnosis and 
treatment of patients with HF. The presence of risk factors for developing HF such as 
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coronary artery disease, hypertension, and diabetes and the presence of substance 
abuse or recent viral syndrome can provide clues for the etiology of HF. Exposure to 
chemotherapeutic agents, endocrine abnormalities, recent pregnancy, family history of 
HF or transplant are all subjects that should be addressed during the initial interview of 
the patient with HF. A comprehensive history will narrow down the extensive list of 
etiologies and allows the clinician to provide a more focused and tailored therapy. 
Physical Exam 
Vital Signs: Evaluation of the HF patient starts with the vital signs. An elevated 
temperature can be present in myocarditis, or acute valvular lesions in infective 
endocarditis. Heart rate and regularity is also an imperative parameter in evaluating a 
patient with HF. Presence of tachycardia is an important and often ominous finding in 
acutely decompensated HF. Blood pressure can vary significantly depending on the 
stage and severity of the disease. HF patient can present to Emergency Room with very 
high systolic and diastolic pressures and acute pulmonary edema. A narrow pulse 
pressure (less than 25%) is a sign of low cardiac output and severely decompensated 
HF patient. 
The patient’s state of mind and clarity can be determined during the interview. Low 
cardiac output can manifest itself as a confused and difficult to arouse patient. 
Evaluation of the jugular venous pressure (JVP) is probably the most important and 
challenging part of the exam of the HF patient. JVP will determine the volume status of 
the patient which will guide the HF therapy. JVP can also differentiate intravascular 
volume overload from extravascular edema present in other conditions.  Presence of 
rales in an acute setting is common, although the absence of rales does not rule out HF 
especially in a patient with chronic HF. The cardiac exam includes the regularity of the 
rhythm, and the presence of murmurs and gallops. A displaced point of maximal 
impulse (PMI) is indicative of an enlarged heart. The abdominal exam includes the size 
of the liver and presence of edema. Ascites, sacral, scrotal, or lower extremity edema 
can be present in a volume overloaded patient with manifestations of right-sided heart 
failure.  Cool extremities and low pulse volume can be another sign of the hypo-
perfused patient with low cardiac output. Palpation of the peripheral pulses can also be 
helpful in assessing cardiac in assessing cardiac performance and stroke volume. A full 
and round pulse as compared to a short and pointed pulse can be the difference in a 
compensated HF patient or a sign of low cardiac output respectively.  
Diagnostic Tests 
Chest X-ray: CXR findings can be specific but not sensitive for diagnosing HF. 
Classically, presence of Kerley B lines, Peribronchial cuffing, pleural effusions, and 
cephalization of the pulmonary vasculature can be present in HF patients. 
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Electrocardiogram: ECG determines the presence of any arrhythmias that are common 
in HF patients. Presence of Q waves, or ischemic changes such as ST elevation or 
depressions vs. left ventricular hypertrophy or low voltage may guide the clinician 
towards the correct etiology of HF.   
Laboratory Data: Patients with acute HF can present with low sodium levels. 
BUN/Creatinine can also be abnormal depending of the degree of decompensation and 
hypoperfusion. B-type natriuretic peptide (BNP), or N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) measurements are useful in an acutely decompensated patient 
(4-5). Although the absolute value of each lab value can be variable, both BNP and NT-
proBNP can be useful in distinguishing HF from other common conditions when clinical 
picture is not clear (Class I indication). Of note, BNP levels can be falsely low in 
morbidly obese patients.  
Other lab values to consider are as following: 
• Troponin 
• Thyroid stimulating hormone (TSH) 
• Iron studies 
• HIV 
• Liver function test (LFT) 
Troponin levels can be elevated in both ischemic and non ischemic HF patients. 
Persistent elevation of troponin levels does have a poor prognostic value in HF patients 
(6). Liver function can also be a marker of the level of congestion and chronicity of HF. 
In appropriate patients, HIV and Iron level are helpful to further narrow down the 
etiology of HF.  
Acute Heart failure Therapy 
Once the underlying cause of HF is identified, the HF therapy can be tailored to the 
individual patient. When evaluating a patient with acute HF, it is important to assess the 
level of congestion, i.e. “wet” vs. “dry” and also the level of perfusion, “warm” vs. “cold”.  
The level of congestion and perfusion of the HF patient will guide the initial therapy. 
Figure 1. provides a quick assessment of the hemodynamic profile of the HF patient.  
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A quick assessment of the hemodynamic profile is critical prior to initiation therapy since 
the spectrum of therapy can be variable and wide. Patient profile A (warm and dry) can 
be managed as outpatient, while patient profile C (cold/wet) will need inotrope or 
mechanical circulatory support.  
 
Diuretics 
Diuretic therapy is initiated in the acute setting to alleviate symptoms. Parenteral diuretic 
therapy should be initiated in an acute setting in a congested patient with adequate 
perfusion. The diuretic dose should be adjusted frequently until adequate response is 
obtained. Most commonly used loop diuretic is furosamide. Other diuretics such as 
bumetanide or torsemide are also utilized for their increased bioavailability in the oral 
form.  
The diuretic effect of loop diuretics can be enhanced by addition of thiazide diuretics 
such as metolazone or spironolactone in a diuretic resistance patient (8).  Renal 
function and electrolytes need to be monitored closely during aggressive parenteral 
diuresis.  
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When compared IV bolus vs. continuous infusion of loop diuretics, the data has not 
shown significant difference between the two strategies (9). The clinician however can 
choose either method if the patient is refractory to the initial therapy. 
 
Parenteral Vasodilators 
Parenteral vasodilators are used as adjuvant therapy to diuretics to relieve congestion 
and dyspnea in acute HF patient without hypotension. This class of medications 
increase systemic perfusion, including the renal system and therefore enhance the 
diuretic effect of loop diuretics.  
Intravenous nitroglycerin can relieve congestion primarily through venodilation. This 
medication is mainly used in hypertensive patients with pulmonary edema.  Intravenous 
nitroglycerin can also relieve symptoms of angina in patients with significant coronary 
disease. This medication is usually effective up to 24 hours. Patients can develop 
tachyphylaxis or resistance to nitroglycerin during this time (10).  
Sodium Nitroprusside is another potent vasodilator used to treat acute HF. This 
medication relieves congestion by dilating the venous and arterial beds and reducing 
the systemic vascular resistance. Arterial line hemodynamic monitoring is usually 
needed during therapy as Nitroprusside can cause precipitous hypotension. Rare 
thiocyanate toxicity can occur with prolonged use particularly in patients with renal 
impairment (11).  
Nesiritide can also be used to relieve symptoms of dyspnea and enhance diuresis in 
acute HF.  As other vasodilators mentioned above, hypotension is a side effect during 
therapy. Brain natriuretic peptide (BNP) levels are not reliable during administration of 
Nesiritide. It is also important to note that the above vasodilators have not shown any 
mortality benefit for HF patient and are only utilized in the acute setting for symptomatic 
relief (12).  
 
 
Beta Blockers 
Beta Blockers (BB) are important class of drugs used in treatment of HF (13). In an 
acute presentation of HF however their use requires some clinical judgment and 
finesse. BB can be initiated at low dose, or continued if the patient is already on BB 
therapy as outpatient, in a well perfused patient. Titration of this class of drugs however 
should be avoided during the acute phase of HF. BB dose should be reduced or 
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stopped in more severe presentation of HF. It is imperative however that the patient be 
initiated on BB therapy prior to discharge to ensure use as transitions of care occur. 
Sinus tachycardia is often present in acute HF presentation. One should refrain from 
titrating the BB dose in order to suppress sinus tachycardia in HF. In an acutely 
decompensated HF, sinus tachycardia is an appropriate and crucial physiological 
response to a low cardiac output state. Sinus tachycardia is usually resolved as the 
hemodynamic profile of the HF patient improves.  
The literature on HF and BB is extensive. There are however mixed results with certain 
BB medications. For that reason, current recommendations encourage clinicians to use 
1 of the 3 BBs that have showed benefit in clinical trials; Bisoprolol, Metoprolol 
Succinate, or Carvedilol. Table 2. Lists the target doses of the BBs in treatment of HF 
(13-16).  
 
Angiotensin-Converting Enzyme Inhibitors 
ACE inhibitors are the cornerstone of HF therapy (17-18). The vasodilation effects of 
ACE inhibitors are key in improving hemodynamics of HF in both acute and chronic 
state. Unlike BBs, ACE inhibitors do exhibit class effect.  In acute HF patient without 
shock or significant renal dysfunction, ACE inhibitors should be initiated at low dose and 
titrated to the maximum tolerated dose. Short acting ACE inhibitors such as Captopril 
can be initiated in the acute setting if there is concern about hypotensive response. If 
tolerated, the short acting Captopril should be switched to a comparable dose of a long 
acting ACE inhibitor such as Lisinopril or Enalapril. Table 2. Lists the target doses of the 
ACE inhibitors in treatment of HF. 
 
Angiotensin-receptor Blockers (ARBs) 
ARBs are also vasodilators that can be utilized instead of ACE inhibitors in patients with 
acute HF (19-21). ARBs are used when patients exhibit ACE inhibitor intolerance such 
as cough. Table 2. Lists the target doses of the ARBs in treatment of HF. 
 
Aldosterone Antagonists 
Utility of aldosterone antagonists such as Spironolactone, or Eplerenone are limited in 
acute HF setting. They are further discussed in the chronic HF section. Aldosterone 
antagonists do facilitate the diuretic effect of loop diuretics in a congested HF patient 
(22-23).  
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Hydralazine/Nitrates 
In HF patients with significant renal dysfunction or uncontrolled hypertension despite 
maximum dose of ACE and BB, afterload reducers such as combination of hydralazine 
and nitrates can be used. While the benefit of hydralazine and nitrates combination has 
been shown mostly in African American population, this combination should be 
considered in non African Americans when ACE/ARB are not tolerated, or resistant 
hypertension is present (24).  
 
Digoxin 
Perhaps one of the oldest medications available, digoxin still has a role in treatment of 
HF patient. Digoxin is also the only safe and effective oral inotrope agent that has been 
identified so far. While this medication does not affect mortality, it has shown to reduce 
hospitalization in HF patient population (25). Digoxin’s ideal use is in HFrEF patients 
with concomitant atrial fibrillation. This medication has a narrow therapeutic index and 
its serum levels should be kept at 0.5 to 0.9 ng/ml. The dose of this medication should 
be reduced in renally impaired patients.  
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Inotropes 
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Inotropic therapy is reserved for severely decompensated HF patient with signs of 
shock or hypo perfusion organ injury. Low cardiac output or shock can be obvious such 
as low pulse pressure, tachycardia, hypotension, and cool extremities. In some cases 
however, signs of low cardiac output can be subtle such as worsening of renal function 
with loop diuretics in a congested patient, changes in mental status, or abnormal liver 
function tests. Invasive hemodynamic monitoring is usually required to assess and 
manage patients with low cardiac output or shock. In this section, we will discuss some 
of the commonly used inotropic agents. 
Milrinone 
Phosphodiesterase (PD) inhibitors block the degradation of cyclic adenosine 
monophosphate leading to an increase in calcium influx into the myocardium and 
enhance contractility. PD inhibitors also have a vasodilatory effect on the pulmonary 
and peripheral circulation. Intravenous milrinone can be considered in HF patients with 
low cardiac output. This medication should be initiated at low dose and titrated to 
achieve acceptable hemodynamics. Since this class of drugs are also potent 
vasodilators, their use should be avoided in severely hypotensive patients. Concomitant 
use of low dose beta blockers is possible with this class of medications since they 
increase contractility independent of the beta adrenergic pathway (26).  
Dobutamine 
Beta adrenergic receptor agonists can also provide enhanced contractility and 
hemodynamic support in severely decompensated HF patients with low cardiac output.  
As compared to PD inhibitors, Dobutamine has a less vasodilatory effect on the 
periphery and is the preferred medication in hypotensive patients. Concomitant use of 
beta blockers, specially the non-selective class, should be avoided as they counteract 
utilizing the same receptor.  
In general, use of intravenous inotropes is a temporary measure to provide 
hemodynamic support as a bridge to recovery or advance therapies (transplant or Left 
ventricular Assist Devices ). Long term use of inotropes should be avoided except as 
palliative therapy in stage D HF patients, once all available therapies have been 
exhausted (27-28).   
Use of agents with both inotropic and vasopressor property such as norepinephrine 
should only be used in profoundly hypotensive patients with hemodynamic collapse or 
sepsis. Pure vasopressors such as phenylephrine should generally be avoided in HF 
patients. 
Mechanical Circulatory Support 
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In critically ill HF patients with severe hemodynamic compromise who are not 
responsive to medical therapy, Mechanical Circulatory Support (MCS) can be utilized to 
provide a bridge to recovery or advanced therapies. Intra-aortic balloon pumps are 
commonly used devices to provide support to an unstable HF patient. There are a 
number of newer MCS devices available for the end-stage patient.  While they all 
provide hemodynamic support for unstable HF patients, one should recognize that each 
device has its challenges and side effects. These devices should only be utilized in 
highly skilled facilities with well trained support staff. Some of the more commonly used 
new devices are listed bellow: 
• Extracorporeal Membrane Oxygenation (ECMO) 
• TandemHeart 
• Impella 
• Centrimag 
 
Chronic Heart Failure Management  
In this section we will discuss management of chronic HF patient in an outpatient 
setting. Most of the initial work up of HF patient is usually done on the initial 
presentation in a hospital setting. It is important to obtain the comprehensive record of 
all the work up of the HF patient and start an individual profile for each patient. 
Outpatient management of HF serves as a checkpoint to address etiology, 
medication/device optimization, symptoms, advance therapies or palliative care.  
Etiology 
Management of HF patients in an outpatient setting begins with further narrowing down 
the differential diagnosis of HF etiologies. This step will ensure that all the reversible 
causes of HF have been investigated and either addressed, or ruled out. Presence of 
coronary disease, resistant hypertension, substance abuse, thyroid abnormalities, 
arrhythmias, and exposure to toxins are a few common and possibly reversible 
etiologies of HF. This information is key in tailoring the outpatient treatment to individual 
HF patients and improving outcomes.  
Medication Optimization 
Management of HF medications is a challenging, yet critical step in the outpatient 
setting.  In patients with HFrEF, every effort should be made to include beta blockers, 
ACE inhibitors and aldosterone antagonists as part of medical therapy of chronic HF. 
The doses of these medications should be titrated up as tolerated by patients (Table 2.). 
Additional medical therapy such as Hydralazine/Nitrates combination, digoxin, and 
diuretics should also be initiated and maintained if HF patient continues to be 
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symptomatic or struggles with volume overload. ARBs should be utilized in HF patients 
who are ACE intolerant.  
Volume Statue and Symptom Surveillance 
Monitoring HF patient’s volume status in an outpatient setting using physical exam 
(JVD, weight, edema) labs (BNP, sodium) and devices is crucial in maintaining the 
patient’s overall quality of life and avoiding hospitalizations.  HF patients should be 
advised to monitor their daily weights and report any sudden significant changes (> 2 
lbs/day or 5 lb/week) to their HF care provider (29). The diuretic therapy can be 
adjusted accordingly.  
New York Heart Association (NYHA) functional classification is a simple and robust way 
of monitoring patients’ symptoms in an outpatient setting. The clinician’s goal is to get 
the HF patient to Class I or II functional class, and escalate the level of care in 
functional classes III, and IV.  
Device Optimization 
Cardiac devices such as Implantable Cardioverter Defibrillator (ICD) or Cardiac 
Resynchronization Therapy (CRT) are now widely used in HFrEF patients who meet 
criteria.  As part of the evaluation of HF patient in an outpatient setting, the clinicians 
should address the patient’s candidacy for device therapy. In general, HFrEF patients 
with ejection fraction less than 35% who are optimized on medical therapy more than 3-
6 months should be considered for ICD implantation. Patients with EF < 35% due to 
acute myocardial infarction should wait for 40 days prior to ICD implantation (30-32). 
ICDs should be reserved for patients with a reasonable expectation of survival in one 
year, and adequate quality of life.  
Patients with HFrEF and wide QRS morphology (ideally left bundle morphology with 
QRS >150 ms) should be referred for CRT evaluation. Persistent right ventricular pacing 
due to atrioventricular block or atrial fibrillation with slow ventricular response are also 
indications for CRT in HFrEF patients.  
 
Referral to Advance Heart Failure Program 
Despite optimal medical therapy, revascularization, and device therapies, a certain 
percentage of HF patients will progress to more advanced stages of the disease. The 
transition of a HF patient from stable on medical therapy, to an advanced stage 
requiring mechanical circulatory support (MCS) or heart transplantation can be subtle. 
Here are some clinical findings that should trigger a referral to an advanced heart failure 
program: 
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-Persistent NYHA class III-IV despite medical/device therapy 
-Deteriorating renal or liver function (BUN>40 mg/dL or creatinine >1.8 mg/dL) 
-Beta blocker or ACE inhibitor intolerance due to hypotension 
-Increasing diuretic requirements (>120 mg/day or equivalent) 
-Recurrent hospitalizations for HF (more than 1 in 6 months) 
It is imperative to realize that once the patient develops irreversible organ damage, 
advanced therapies such as heart transplantation and Left Ventricular Assist Devices 
(LVADs) may no longer be options. Therefore, timely referral to heart failure program is 
important.   
 
Hospice 
As mentioned at the beginning of this chapter there are over 5 million patients who 
suffer from heart failure. Approximately, 5% of the HF patient population is classified as 
NYHA IV, stage D.  A small portion of the NYHA IV patients will receive heart 
transplantation or LVAD therapy, however, majority of them will not be candidates for 
advanced therapies with very poor outcomes (Figure 2).  Patients with end stage HF 
have recurrent hospitalizations, deteriorating renal function, and poor quality of life. The 
patients and their caregivers are also burdened with significant physical and emotional 
stress at the final moths of life (32). Since the trajectory of end stage heart failure is well 
known and documented, it is imperative for the physician to recognize and address 
such situations. Listed below are some of the signs that should prompt the clinician to 
start the end of life discussion with the patient and their family. 
-NYHA IV symptoms despite optimal medical, surgical, and device therapies 
-Deemed a poor candidate for transplant or LVAD 
-Recurrent hospitalizations despite good compliance 
-Persistent ventricular arrhythmias despite medical and surgical interventions 
-Profound cardiac cachexia  
End of life discussions are always difficult, both for the patient and clinicians. The 
primary physician’s role is crucial in approaching the end stage patient, as they usually 
have a closer and longer bond with the patient and their family. Some of the common 
symptoms of end stage HF are dyspnea, fatigue, pain, anorexia and cachexia. 
Management of the HF patient in the palliative care and hospice stage focuses on 
patient’s comfort and quality of life. 
Dyspnea can be treated with continuous infusion of home inotropes. Nitrates, opioids 
and home oxygen are also effective in alleviating breathlessness. Caffeine and certain 
stimulants have been used to address fatigue in certain HF patients. Titrating down the 
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dosage of beta blockers and ACE inhibitors, or stopping a class of medication 
altogether can also be considered in hypotensive patients.  
End stage HF patients are prone to tachyarrhythmias and recurrent ICD shocks. ICD 
therapy should also be discussed with the patient and the family. While discontinuing 
the defibrillating capability of the ICDs is a reasonable approach, the CRT portion of the 
devices should be continued as it may provide symptom relief.  
 
 
 
 
 
 
 
 
 15 
 
 
 
References 
1. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al. Hospitalization epidemic in 
patients with heart failure: risk factors, risk prediction, knowledge gaps, and future 
directions. J Card Fail. 2011;17:54-75. 
 
2. Fang J, Mensah GA, Croft JB, et al. Heart failure-related hospitalization in the U.S., 
1979 to 2004. J Am Coll Cardiol. 2008;52:428-34. 
 
3. Nohria, A., Mielniczuk, L.M., Stevenson, L.W.  Evaluation and monitoring of patients 
with acute heart failure syndromes. Am J Cardiol. 2005 Sep 19;96(6A):32G-40G. 
 
 
 16 
4. Januzzi JL, Jr., Sakhuja R, O'donoghue M, et al. Utility of amino-terminal pro-brain 
natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea 
treated in the emergency department. Arch Intern Med. 2006;166:315-20. 
 
5. Januzzi JL, Jr., Rehman S, Mueller T, et al. Importance of biomarkers for long-term 
mortality prediction in acutely dyspneic patients. Clin Chem. 2010;56:1814-21. 
 
6. Horwich TB, Patel J, MacLellan WR, et al. Cardiac troponin I is associated with 
impaired hemodynamics, progressive left ventricular dysfunction, and increased 
mortality rates in advanced heart failure. Circulation. 2003;108:833-8. 
 
7. Stevenson LW, Nohria, A, et al. Medical Management of Advanced Heart Failure, 
Journal of the American Medical Association. 2002;287(5):628-640. 
 
8. Rosenberg J, Gustafsson F, Galatius S, et al. Combination therapy with metolazone 
and loop diuretics in outpatients with refractory heart failure: an observational study 
and review of the literature. Cardiovasc Drugs Ther. 2005;19:301-6. 
 
9. Salvador DR, Rey NR, Ramos GC, et al. Continuous infusion versus bolus injection 
of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 
2005;CD003178. 
 
10. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive 
heart failure: a randomized controlled trial. JAMA. 2002;287:1531-40. 
 
11. Cioffi G, Stefenelli C, Tarantini L, et al. Hemodynamic response to intensive 
unloading therapy (furosemide and nitroprusside) in patients >70 years of age with 
left ventricular systolic dysfunction and decompensated chronic heart failure. Am J 
Cardiol. 2003;92:1050-6. 
 
12. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic 
peptide, in the treatment of decompensated congestive heart failure. Nesiritide 
Study Group. N Engl J Med. 2000;343:246-53. 
 
13. Butler J, Young JB, Abraham WT, et al. Beta-blocker use and outcomes among 
hospitalized heart failure patients. J Am Coll Cardiol. 2006;47:2462-9. 
 17 
 
14. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. 
N Engl J Med. 2001;344:1659-67. 
 
15. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart 
failure due to ischemic heart disease. Australia-New Zealand Heart Failure 
Research Collaborative Group. Circulation. 1995;92:212-8. 
 
16. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation 
or withdrawal on outcomes in patients hospitalized with heart failure: findings from 
the OPTIMIZE-HF program. J Am Coll Cardiol. 2008;52:190-9. 
 
17. Effects of enalapril on mortality in severe congestive heart failure. Results of the 
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The 
CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-35. 
 
18. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-
converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction 
after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. 
N Engl J Med. 1995;333:1670-6. 
 
19. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker 
valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75. 
 
20. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients 
with chronic heart failure and reduced left-ventricular systolic function taking 
angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 
2003;362:767-71. 
 
21. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with 
chronic heart failure and reduced left-ventricular systolic function intolerant to 
angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 
2003;362:772-6. 
 
 18 
22. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in 
patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 
2003;348:1309-21. 
 
23. Butler J, Ezekowitz JA, Collins SP, et al. Update on aldosterone antagonists use in 
heart failure with reduced left ventricular ejection fraction heart failure society of 
america guidelines committee. J Card Fail. 2012;18:265-81. 
 
24. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and 
hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-57. 
 
25. The effect of digoxin on mortality and morbidity in patients with heart failure. The 
Digitalis Investigation Group. N Engl J Med. 1997;336:525-33. 
 
26. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with 
increased short-term mortality in hospitalized patients with worsening heart failure: 
results from the Outcomes of a Prospective Trial of Intravenous Milrinone for 
Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 
2005;111:2454-60. 
 
27. Aranda JM, Jr., Schofield RS, Pauly DF, et al. Comparison of dobutamine versus 
milrinone therapy in hospitalized patients awaiting cardiac transplantation: a 
prospective, randomized trial. Am Heart J. 2003;145:324-9. 
 
28. Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobutamine or 
milrinone infusions for stage D heart failure. Circ Heart Fail. 2009;2:320-4. 
 
29. Abraham WT, Compton S, Haas G, et al. Intrathoracic impedance vs daily weight 
monitoring for predicting worsening heart failure events: results of the Fluid 
Accumulation Status Trial (FAST). Congest Heart Fail. 2011;17:51-5. 
 
30. Zareba W, Piotrowicz K, McNitt S, et al. Implantable cardioverter-defibrillator 
efficacy in patients with heart failure and left ventricular dysfunction (from the 
MADIT II population). Am J Cardiol. 2005;95:1487-91. 
 
 19 
31. Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of 
ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator 
Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol. 
2011;57:2416-23. 
 
32. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative 
meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, 
DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac 
resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501-8. 
 
33. Adler ED, Goldfinger JZ, Kalman J, et al. Palliative care in the treatment of 
advanced heart failure. Circulation. 2009;120:2597-606. 
 
 
